Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

FLT-1 blockers, cutting the legs of leukaemia

15.11.2005


Leukaemia is characterised by an uncontrolled growth of abnormal blood cells in the bone marrow (BM). Escape of the cancerous cells to other organs is linked with worst disease prognosis and less susceptibility to therapy, and, as consequence, to understand the mechanism(s) behind such migration is crucial. And now, in an advance online publication of the journal "Blood", a group of researchers has found that FLT-1 - a molecule implicated in blood vessel growth – is necessary for the escape of the leukaemia cells from the BM, suggesting that blocking of this molecule might be used in the treatment of leukemia.



Leukaemia, or cancer of the white blood cells, affects 4 out of 100,000 people worldwide and in the United States alone more than 2,000 children and 27,000 adults are diagnosed with the disease every year. The illness originates from an abnormal multiplication of the cancerous cells in the BM that leaves little no space for normal blood cells to grow resulting in an impaired immune system that, among other problems, is incapable of efficiently fight infection.

It is known that leukaemia development, like it happens with solid tumours, depends on the development of extra blood vessels (a process known as vascularisation), which serve to supply the fast multiplying cancerous cells with nutrients and help rapid cancer expansion and often metastasis formation. Interestingly, it has also been found that molecules involved in vascularisation seem to be capable of act directly on the cancerous cells. One such example is VEGF (Vascular Endothelial Growth Factor) that appears to affect division, survival and migration of cancer cells and consequently cancer growth and dissemination.


FLT-1 or “Vascular endothelial growth factor receptor”, which binds to VEGF, is another molecule involved in vascularisation that has been suggested to have a role in the division and migration of cancer cells. This observation, together with the fact that FLT-1 is produced in high quantities by leukaemia cells, have led Rita Fragoso, Teresa Pereira, Sérgio Dias and colleagues in Portugal and the United States to investigate the role of FLT-1 in this disease.

For that the group of investigators used cells from patients with ALL, the most common childhood leukaemia, and one in which the abnormally proliferating cells are immature blood cells called lymphoblasts. Cells from different ALL patients, which produced distinct amounts of FLT-1, were injected into mice with no blood cells and followed in order to understand how different quantities of this molecule could affect cell fate and disease progression.

What they found was that FLT-1 levels influenced both migration and cell survival, and therefore also disease outcome.

In fact, cells expressing high quantities of FLT-1 were found in the “exit area” of the BM (from where blood cells migrate into the periphery), in the peripheral circulation and also in other organs, such as the spleen and liver. Cells with low or no FLT-1, on the other hand, stayed within the BM where part of them die. As consequence, animals injected with these last cells presented a slower spread of leukaemia and a higher survival rate than animals injected with cells producing high quantities of FLT-1. Further experiments showed that the different patterns of migration were associated with a gradient of VEGF (which binds FLT-1) found throughout the BM.

What these results showed for the first time was that the localisation of different subsets of leukaemia cells within the BM was dependent on their FLT-1 production, and that different localisations affected cell survival and leukemia expansion and consequently also the survival of animals/patients suffering from the disease.

This work has helped to understand better the biology of leukaemia cells within the BM, how they behave and why, and also the importance of what happens within this organ in disease severity and treatment susceptibility. In fact, migration of ALL cells to outside of the BM not only correlates with a more severe disease but also with a worst response to treatment, since these cells will be less accessible to therapy when spread throughout the body than when restricted to a small area.

But what is more important is that, in view of Fragoso, Pereira, Dias and colleagues’ results, FLT-1 blockers appear as a promising new treatment against leukaemia. And if they are used in combination with chemotherapy they will be able – as result of the cells being more readily available to the injected drugs when stopped within the BM- to increase treatment effectiveness what is certainly good news to patients all over the world.

Piece researched and written by: Catarina Amorim (catarina.amorim@linacre.ox.ac.uk)

Catarina Amorim | alfa
Further information:
http://www.bloodjournal.org/cgi/reprint/2005-06-2530v1

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>